• news.cision.com/
  • Bioservo AB/
  • Communication from the Exraordinary General Meeting of Bioservo Technologies AB (publ) held September 10, 2019

Communication from the Exraordinary General Meeting of Bioservo Technologies AB (publ) held September 10, 2019

Report this content

Today, the Extraordinary General Meeting of Bioservo approved, in accordance with the proposal in the notice, the Board of Directors’ decision on the issue of new shares.


The decision results in an increase in Bioservo’s share capital by a maximum of SEK 1,072,374 through the issue of a maximum of 5,361,870 shares. The subscription price in the issue amounts to SEK 12 per share, which means that Bioservo will receive approximately SEK 64.3 million, before transaction costs, if the issue is fully subscribed. Bioservo’s shareholders have preferential rights to subscribe for the new shares in relation to the number of shares they previously own.

The record date for participation in the rights issue is September 12, 2019.

The subscription period for the issue will be during the period from September 16 to September 30, 2019. The Board of Directors shall have the right to extend the subscription period.

For detailed terms regarding the decision at the Extraordinary General Meeting, please refer to the complete proposal available on Bioservo’s website, www.bioservo.com.


For further information please contact:

Petter Bäckgren



+46 8 21 17 10


Jacob Michlewicz



+46 8 21 17 10


About Bioservo Technologies

Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology –wearable non-invasive devices –for people in need of extra power to optimize the body’s endurance and performance, or for people with reduced muscle strength.

Bioservo Technologies AB was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska Hospital. Since its inception, Bioservo Technologies AB has further developed its acclaimed and patented SEM ™ technology (Soft Extra Muscle) and is the world leader in wearable soft robotics.

Bioservo Technologies is dedicated to becoming the world-leading developer of wearable technologies based on bionic soft robotics.

The commitment is based on a true belief that this technology will change the lives for many people, enhancing their independence and quality-of-life. Our innovative solutions are already delivering future business opportunities and breakthrough technologies. We are extremely proud to have been top ranked for our technological and innovative progress in both Europe and in Sweden. Our revolutionary SEM™ (Soft Extra Muscle) technology was invented by Professor Hans von Holst (neurosurgery), Professor Jan Wikander and Doctor Johan Ingvast, PhD (mechatronic engineering).

FNCA Sweden AB, +46(0)8-52800399, info@fnca.se is the company’s Certified Adviser on Nasdaq First North

For more information, please visit www.bioservo.com

Note This information is such as is required by Bioservo Technologies AB under the EU Market Abuse Regulation and the Securities Market Act. The information was submitted, through the care of the above person, for publication on September 10, 2019 at 12:30.


Documents & Links